CTOs on the Move


 
Novum is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

XIL Consulting

PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.

PhysIq

physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies

Alfa Aesar

Alfa Aesar, a Johnson Matthey Company, is a leading international manufacturer and supplier of research chemicals, metals and materials. With 30,000 products listed in the catalogue, Alfa Aesar is the single source for customers' chemical and material

Bio-Boiler Systems Inc

Bio-Boiler Systems Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.